Clinical trial
A Randomized,Double-blind,Vehicle-controlled, Parallel-design,Multiple-site Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Douglas Pharmaceuticals America Ltd) to Ketoconazole Cream 2% (Teva Pharmaceuticals USA Inc.) in the Treatment of Tinea Pedis.
NCT04203342 is registered in ClinicalTrials.gov with Douglas Pharmaceuticals America Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized,Double-blind,Vehicle-controlled, Parallel-design,Multiple-site Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Douglas Pharmaceuticals America Ltd) to Ketoconazole Cream 2% (Teva Pharmaceuticals USA Inc.) in the Treatment of Tinea Pedis.
- Lead sponsor
- Douglas Pharmaceuticals America Ltd
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 11, 2019
- Completion date
- July 13, 2020
- Enrollment
- 682 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.